AVALO THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $66.00K, a 65.00% increase year-over-year.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was -$17.00K.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $40.00K.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $23.00K, a 66.18% decline from fiscal 2024.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $68.00K, a 1.49% increase from fiscal 2023.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $67.00K, a 8.22% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $73.00K, a 80.05% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $66.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $23.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $40.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $68.00K 10-K · filed 2026-03-23 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $67.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $67.00K 10-Q · filed 2024-08-12 | |
| 2022-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $73.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $25.00K 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $366.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | |
| 2021-06-30 | $207.00K 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $312.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | |
| 2020-06-30 | $133.00K 10-Q · filed 2021-08-02 | |
| 2019-12-31 | $83.24K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $210.78K 10-K · filed 2021-03-08 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2019-06-30 | $127.54K 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $63.84K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $72.24K 10-K · filed 2020-03-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $8.40K 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $46.86K 10-K · filed 2019-03-18 | |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |